

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

MFE-280

RRID:CVCL_1405

Type: Cell Line

Proper Citation

RRID:CVCL_1405

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1405

Proper Citation: RRID:CVCL_1405

Description: Cell line MFE-280 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Endometrial adenocarcinoma

Defining Citation: [PMID:9615781](#), [PMID:9620227](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MFE-280

Synonyms: MFE 280, MFE280

Cross References: CLO:CLO_0007692, CLDB:cl5080, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:941, BioSample:SAMN03473586, BioSample:SAMN10987795, cancercellines:CVCL_1405, Cell_Model_Passport:SIDM00335, ChEMBL-Cells:ChEMBL3308455, ChEMBL-Targets:ChEMBL1075502, Cosmic:908129, Cosmic:1434185, Cosmic:1576462, Cosmic:2030478, Cosmic-CLP:908129, DepMap:ACH-000192, DSMZ:ACC-410, DSMZCellDive:ACC-410, ECACC:98050131,

EGA:EGAS00001000978, GDSC:908129, GEO:GSM374974, GEO:GSM375433, GEO:GSM844603, GEO:GSM887311, GEO:GSM888387, GEO:GSM1670098, IARC_TP53:21495, LiGeA:CCLE_689, LINCS_LDP:LCL-1500, PharmacDB:MFE280_919_2019, PRIDE:PXD030304, Progenetix:CVCL_1405, PubChem_Cell_line:CVCL_1405, Ubigen:YC-C101, Wikidata:Q54905380

ID: CVCL_1405

Record Creation Time: 20220427T220804+0000

Record Last Update: 20260905T181139+0000

Ratings and Alerts

No rating or validation information has been found for MFE-280.

No alerts have been found for MFE-280.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. *Molecular cancer therapeutics*.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Khan S, et al. (2023) Reducing the Invasiveness of Low- and High-Grade Endometrial Cancers in Both Primary Human Cancer Biopsies and Cell Lines by the Inhibition of Aquaporin-1 Channels. *Cancers*, 15(18).

Zhang W, et al. (2023) HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation. *Cell reports*, 42(11), 113352.

Yamato M, et al. (2022) DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models. *Molecular cancer therapeutics*, 21(4), 635.

Mukherjee R, et al. (2021) Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. *Molecular cell*, 81(4), 708.

Xu H, et al. (2021) CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. *Cell reports. Medicine*,

2(9), 100394.